A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Journal of substance abuse treatment July 1, 2022 Patrick Köck, Katharina Froelich, Marc Walter et al. 68 citations
Ibogaine and its alkaloids reduce withdrawal symptoms and craving in substance use disorders, and may also improve depression and trauma-related symptoms. However, severe medical complications and deaths have been reported, linked to neuro- and cardiotoxic effects. Two fatalities occurred among 705 individuals across 24 studies, which included two randomized controlled trials and 17 open-label studies. Ibogaine's distinct psychoactive and somatic effects set it apart from classic hallucinogens like LSD and psilocybin. Rigorous medical monitoring is needed for safe application.